A blind man can make out objects again after an optogenetics treatment


The doctors employed gene therapy to add a light-sensing molecule to one of the man’s eyes. The gene they added, called chrimson, comes from a single-celled algae species that is able to sense sunlight and move toward it.

The idea of adding the gene, says Roska, is to engineer retina cells called ganglions so they are able to respond to light, sending visual signals to the brain.

The strategy, being funded by a French company called GenSight Biologics, requires patients to wear a set of electronic goggles that capture light contrasts in the environment and then project an image onto the retina at high intensity using the specific wavelength of yellow-orange light that triggers the chrimson molecule.

A blind patient treated with a novel form of gene therapy employs a set of goggles to try to count objects placed in his field of view. He is wearing an EEG cap so that researchers can measure his brain’s response to light.

NATURE

According to José-Alain Sahel, a researcher at the University of Pittsburgh who played a chief role in the experiment and is a cofounder of GenSight, the blind man at first noticed no effect, but he gradually started reporting seeing shapes while wearing the goggles. Sahel describes the patient as “the first ever to benefit from optogenetics.”

With training, the man was able to perceive whether a notebook had been placed on a table in front of him. He could also count dark-colored cups set before him, although not always accurately.

Optogenetics is widely used in neuroscience experiments on animals, where the light-sensing molecules are added to brain cells. Then, using light pulses delivered via fiber-optic cables, researchers can cause specific nerves to fire, in some cases to prompt specific behaviors.

Efforts to adapt the technique as a blindness cure began in 2016, when a Texas woman became the first person treated with optogenenetics by a small company, RetroSense, that was later acquired by Allergan. The results of that study were never publicly reported, although Allergan officials later said some patients claimed to see light, such as perceiving a bright window in a dark room.

Vedere Bio, a startup in Cambridge, Massachusetts, has also been developing optogenetic treatments.

According to Roska and Sahel, several patients have now been treated in the clinical trial being sponsored by GenSight, but only the man whose case is being described today has used the goggles.

The level of vision restored to the patient remains extremely limited. What he sees through the googles is monochromatic, and the resolution is not high enough to read, or even to distinguish one object from another.

The researchers said the goggles would likely be refined and that with more training, the man might be able to see more than he does now. “The level of vision we are going to reach is impossible to predict,” says Sahel.


The doctors employed gene therapy to add a light-sensing molecule to one of the man’s eyes. The gene they added, called chrimson, comes from a single-celled algae species that is able to sense sunlight and move toward it.

The idea of adding the gene, says Roska, is to engineer retina cells called ganglions so they are able to respond to light, sending visual signals to the brain.

The strategy, being funded by a French company called GenSight Biologics, requires patients to wear a set of electronic goggles that capture light contrasts in the environment and then project an image onto the retina at high intensity using the specific wavelength of yellow-orange light that triggers the chrimson molecule.

A blind patient treated with a novel form of gene therapy employs a set of goggles to try to count objects placed in his field of view. He is wearing an EEG cap so that researchers can measure his brain’s response to light.

NATURE

According to José-Alain Sahel, a researcher at the University of Pittsburgh who played a chief role in the experiment and is a cofounder of GenSight, the blind man at first noticed no effect, but he gradually started reporting seeing shapes while wearing the goggles. Sahel describes the patient as “the first ever to benefit from optogenetics.”

With training, the man was able to perceive whether a notebook had been placed on a table in front of him. He could also count dark-colored cups set before him, although not always accurately.

Optogenetics is widely used in neuroscience experiments on animals, where the light-sensing molecules are added to brain cells. Then, using light pulses delivered via fiber-optic cables, researchers can cause specific nerves to fire, in some cases to prompt specific behaviors.

Efforts to adapt the technique as a blindness cure began in 2016, when a Texas woman became the first person treated with optogenenetics by a small company, RetroSense, that was later acquired by Allergan. The results of that study were never publicly reported, although Allergan officials later said some patients claimed to see light, such as perceiving a bright window in a dark room.

Vedere Bio, a startup in Cambridge, Massachusetts, has also been developing optogenetic treatments.

According to Roska and Sahel, several patients have now been treated in the clinical trial being sponsored by GenSight, but only the man whose case is being described today has used the goggles.

The level of vision restored to the patient remains extremely limited. What he sees through the googles is monochromatic, and the resolution is not high enough to read, or even to distinguish one object from another.

The researchers said the goggles would likely be refined and that with more training, the man might be able to see more than he does now. “The level of vision we are going to reach is impossible to predict,” says Sahel.

Leave a Comment

Your email address will not be published. Required fields are marked *